Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apolipoprotein L1 Gene Effects on Kidney Transplantation.

Literature DB >> 29110760

Apolipoprotein L1 Gene Effects on Kidney Transplantation.

Barry I Freedman¹, Jayme E Locke², Amber M Reeves-Daniel³, Bruce A Julian⁴.

Abstract

The pathogenesis of many common etiologies of nephropathy has been informed by recent molecular genetic breakthroughs. It now is apparent that the ethnic disparity in the risk for nondiabetic chronic kidney disease between African Americans and European Americans is explained largely by variation in the apolipoprotein L1 gene (APOL1). The presence of two APOL1 renal risk variants markedly increases an individual's risk for kidney disease. In transplantation, kidneys from deceased African Americans with two APOL1 renal risk variants have shorter survival intervals after engraftment, regardless of the ethnicity of the recipient. Precision medicine will transform the clinical practice of nephrology and kidney transplantation, and play an important role in the allocation of kidneys from deceased and living kidney donors with recent African ancestry. This article reviews existing data on APOL1 in deceased-donor and living-donor kidney transplantation. It considers the impact of including APOL1 genotyping in decisions on the allocation and discard of deceased-donor kidneys, as well as the selection of living donors.

Entities: Chemical Disease Gene Species

Keywords: APOL1; African American; allocation; chronic kidney disease; kidney transplantation; organ donation

Mesh：

Substances：

Year: 2017 PMID： 29110760 PMCID： PMC5683426 DOI： 10.1016/j.semnephrol.2017.07.006

Source DB: PubMed Journal: Semin Nephrol ISSN： 0270-9295 Impact factor: 5.299

35 in total

1. APOL1 and progression of nondiabetic nephropathy.

Authors: Nicholette D Palmer; Barry I Freedman
Journal: J Am Soc Nephrol Date: 2013-06-27 Impact factor: 10.121

2. African American living-kidney donors should be screened for APOL1 risk alleles.

Authors: David M Cohen; Anuja Mittalhenkle; David L Scott; Carlton J Young; Douglas J Norman
Journal: Transplantation Date: 2011-10-15 Impact factor: 4.939

3. The APOL1 gene and allograft survival after kidney transplantation.

Authors: A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman
Journal: Am J Transplant Date: 2011-04-12 Impact factor: 8.086

Review 4. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

Authors: Barry I Freedman; Jeffrey B Kopp; Carl D Langefeld; Giulio Genovese; David J Friedman; George W Nelson; Cheryl A Winkler; Donald W Bowden; Martin R Pollak
Journal: J Am Soc Nephrol Date: 2010-08-05 Impact factor: 10.121

5. Perioperative mortality and long-term survival following live kidney donation.

Authors: Dorry L Segev; Abimereki D Muzaale; Brian S Caffo; Shruti H Mehta; Andrew L Singer; Sarah E Taranto; Maureen A McBride; Robert A Montgomery
Journal: JAMA Date: 2010-03-10 Impact factor: 56.272

6. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.

Authors: B T Lee; V Kumar; T A Williams; R Abdi; A Bernhardy; C Dyer; S Conte; G Genovese; M D Ross; D J Friedman; R Gaston; E Milford; M R Pollak; A Chandraker
Journal: Am J Transplant Date: 2012-04-04 Impact factor: 8.086

7. Perceptions regarding genetic testing in populations at risk for nephropathy.

Authors: Barry I Freedman; Alison J Fletcher; Vivek R Sanghani; Mitzie Spainhour; Angelina W Graham; Gregory B Russell; Jessica N Cooke Bailey; Ana S Iltis; Nancy M P King
Journal: Am J Nephrol Date: 2013-11-21 Impact factor: 3.754

8. Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate.

Authors: Morgan E Grams; Yingying Sang; Andrew S Levey; Kunihiro Matsushita; Shoshana Ballew; Alex R Chang; Eric K H Chow; Bertram L Kasiske; Csaba P Kovesdy; Girish N Nadkarni; Varda Shalev; Dorry L Segev; Josef Coresh; Krista L Lentine; Amit X Garg
Journal: N Engl J Med Date: 2015-11-06 Impact factor: 91.245

9. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes.

Authors: Ajay K Israni; Nicholas Salkowski; Sally Gustafson; Jon J Snyder; John J Friedewald; Richard N Formica; Xinyue Wang; Eugene Shteyn; Wida Cherikh; Darren Stewart; Ciara J Samana; Adrine Chung; Allyson Hart; Bertram L Kasiske
Journal: J Am Soc Nephrol Date: 2014-05-15 Impact factor: 10.121

10. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors: Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal: Hum Genet Date: 2010-07-16 Impact factor: 4.132

16 in total

Apolipoprotein L1 Gene Effects on Kidney Transplantation.

1. APOL1 and progression of nondiabetic nephropathy.

2. African American living-kidney donors should be screened for APOL1 risk alleles.

3. The APOL1 gene and allograft survival after kidney transplantation.

Review 4. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

5. Perioperative mortality and long-term survival following live kidney donation.

6. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.

7. Perceptions regarding genetic testing in populations at risk for nephropathy.

8. Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate.

9. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes.

10. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Review 1. The Impact of APOL1 on Chronic Kidney Disease and Hypertension.

2. Xenotransplantation.

3. Evaluation of Potential Living Kidney Donors in the APOL1 Era.

4. The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO.

5. Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.

Review 6. APOL1 Genetic Testing in Living Kidney Transplant Donors.

Review 7. Apolipoprotein L1 nephropathies: 2017 in review.

Review 8. APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.

9. APOL1 genotyping in kidney transplantation: to do or not to do, that is the question? (pro).

10. Variation of ApoL1 Testing Practices for Living Kidney Donors.